2010
DOI: 10.1111/j.1349-7006.2010.01509.x
|View full text |Cite
|
Sign up to set email alerts
|

Clinical study of asbestos‐related lung cancer in Japan with special reference to occupational history

Abstract: A total of 152 patients with asbestos-related lung cancer recognized by the criteria of Japanese compensation law for asbestosrelated diseases were examined and compared with 431 patients with non-asbestos-related lung cancer. Male comprised 96% of patients. Ages ranged from 50 to 91 years with a median of 72 years. Eighty-nine percent were smokers or ex-smokers. Almost all patients had occupational histories of asbestos exposure. The median duration of asbestos exposure was 31 years and the median latency per… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
20
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 16 publications
(26 citation statements)
references
References 13 publications
6
20
0
Order By: Relevance
“…Our results provide support for these previous findings and suggest that DPT can develop after moderate-to-high levels of exposure to asbestos, because the occupational category of the subjects in the current study included those of relatively high levels of asbestos exposure, such as asbestos product manufacturing and shipbuilding. The median latency period between asbestos exposure and DPT development in the present study was similar to that observed for malignant mesothelioma and lung cancer in our previous reports [15,16,17] and that for DPT in another report by Kee et al [18]. …”
Section: Discussionsupporting
confidence: 77%
“…Our results provide support for these previous findings and suggest that DPT can develop after moderate-to-high levels of exposure to asbestos, because the occupational category of the subjects in the current study included those of relatively high levels of asbestos exposure, such as asbestos product manufacturing and shipbuilding. The median latency period between asbestos exposure and DPT development in the present study was similar to that observed for malignant mesothelioma and lung cancer in our previous reports [15,16,17] and that for DPT in another report by Kee et al [18]. …”
Section: Discussionsupporting
confidence: 77%
“…Regarding survival, we cannot state that the patients in this study with asbestos‐related lung cancer diagnosed by regular medical examination did not have an inferior prognosis to previously reported patients with non‐asbestos‐related lung cancer because of small sample size. It was reported that the prognosis of asbestos‐related lung cancer patients who underwent surgical treatment was better than that of patients for whom surgery was not indicated due to advanced clinical stage, which is compatible with our results.…”
Section: Discussionsupporting
confidence: 92%
“…This criterion may not be applicable to some patients with chrysotile exposure. For the certification of workers' compensation, other administratively estimated criteria are applicable to such patients, including (i) asbestosis on CXR; (ii) pleural plaques with more than 10 years' occupational asbestos exposure; and (iii) asbestos bodies or fibers in the lung tissues with more than 10 years' occupational asbestos exposure [Kishimoto et al, 2010]. In addition, lung cancer patients who have PABCs between 1,000 and 5,000 AB/g dry lung have their lung tissue examined for their asbestos fibers by analytical transmission electron microscopy.…”
Section: Discussionmentioning
confidence: 99%
“…In the Japanese compensation and relief systems, PABC has been used as one of the eligible criteria for lung cancer caused by asbestos. People are deemed to have lung cancer caused by asbestos and are eligible for compensation and relief benefits if they have a PABC of !5,000 asbestos bodies per gram of dry lung tissue [Kishimoto et al, 2010]. Our research group has been measuring PABC to evaluate the cumulative exposure levels in lung cancer patients.…”
Section: Introductionmentioning
confidence: 99%